The use of haploidentical stem cell transplant as an alternative donor source in patients with decreased access to matched unrelated donors

References

• Rocha V, Fatobene G, Niederwieser D. Increasing access to allogeneic hematopoietic cell transplant: an international perspective. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):264–274. doi:10.1182/hematology.2021000258. PMID: 34889391; PMCID: PMC8791161.
   PubMedGoogle Scholar
• Krummey SM, Gareau AJ. Donor specific HLA antibody in hematopoietic stem cell transplantation: implications for donor selection. Front Immunol. 2022;13:916200. Published 2022 Aug 5. doi:10.3389/fimmu.2022.916200
   PubMedGoogle Scholar
• Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014 Jul 24;371(4):339–348. doi:10.1056/NEJMsa1311707. PMID: 25054717; PMCID: PMC5965695.
   PubMed Web of Science ®Google Scholar
• Lown RN, Marsh SGE, Blake H, et al. Equality of access to transplant for ethnic minority patients through use of cord blood and haploidentical transplants. Blood. 2013;122(21):2138. doi:10.1182/blood.V122.21.2138.2138
   Google Scholar
• Spellman SR. Hematology 2022-what is complete HLA match in 2022? Hematology Am Soc Hematol Educ Program. 2022;2022(1):83–89. doi:10.1182/hematology.2022000326
   PubMedGoogle Scholar
• Howard CA, Fernandez-Vina MA, Appelbaum FR, et al. Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2015;21(1):4–7. doi:10.1016/j.bbmt.2014.09.017
   PubMed Web of Science ®Google Scholar
• Kanda J. Effect of HLA mismatch on acute graft-versus-host disease. Int J Hematol. 2013;98:300–308. doi:10.1007/s12185-013-1405-x
   PubMed Web of Science ®Google Scholar
• Dehn J, Spellman S, Hurley CK, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019 Sep 19;134(12):924–934. Epub 2019 Jul 10. Erratum for: doi:10.1182/blood.2019002898. PMID: 31292117; PMCID: PMC6753623.
   PubMedGoogle Scholar
• Ramsey SD, Bansal A, Li L, et al. Cost-effectiveness of unrelated umbilical cord blood transplantation versus HLA-haploidentical related bone marrow transplantation: evidence from BMT CTN 1101. Transplant Cell Ther. 2023;29(7):464.e1–464.e8. doi:10.1016/j.jtct.2023.04.017
   PubMedGoogle Scholar
• Hwang WY, Kongtim P, Majhail NS, et al. Alternate donor transplantation. Blood Cell Ther. 2022 Dec 23;5(Spec Edition):S6–S14. doi:10.31547/bct-2022-012. PMID: 37220609; PMCID: PMC10200364.
   PubMedGoogle Scholar
• Montoro J, Sanz J, Sanz FJ, et al. Advances in haploidentical stem cell transplantation for hematologic malignancies. Leuk Lymphoma. 2016;57(8):1766–1775. doi:10.3109/10428194.2016.1167204
   PubMed Web of Science ®Google Scholar
• Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016 Jan;13(1):10–24. doi:10.1038/nrclinonc.2015.128. Epub 2015 Aug 25. Erratum in: Nat Rev Clin Oncol. 2016 Feb;13(2):132. PMID: 26305035; PMCID: PMC4695979.
   PubMed Web of Science ®Google Scholar
• Hansen JA, Clift RA, Mickelson EM, et al. Marrow transplantation from donors other than HLA identical siblings. Hum Immunol. 1981;2(1):31–40. doi:10.1016/0198-8859(81)90004-5
   PubMed Web of Science ®Google Scholar
• Powles RL, Morgenstern GR, Kay HE, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet. 1983;321(8325):612–615. doi:10.1016/S0140-6736(83)91793-2
   Google Scholar
• Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313(13):765–771. doi:10.1056/NEJM198509263131301
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Thall PF, Wang X, et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011;118(22):5957–5964. doi:10.1182/blood-2011-06-362111
   PubMed Web of Science ®Google Scholar
• Ciurea SO, de Lima M, Cano P, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009 Oct 27;88(8):1019–1024. doi:10.1097/TP.0b013e3181b9d710. PMID: 19855248; PMCID: PMC4324621.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Thall PF, Milton DR, et al. Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol Blood Marrow Transplantation. 2015;21(8):1392–1398. doi:10.1016/j.bbmt.2015.05.001
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Cao K, Fernandez-Vina M, et al. The European society for blood and marrow transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2018 May;53(5):521–534. doi:10.1038/s41409-017-0062-8. Epub 2018 Jan 15. Erratum in: Bone Marrow Transplant. 2018 Sep 19;: PMID: 29335625; PMCID: PMC7232774.
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84(11):3948–3955. doi:10.1182/blood.V84.11.3948.bloodjournal84113948
   PubMed Web of Science ®Google Scholar
• Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112(9):3574–3581. doi:10.1182/blood-2008-02-140095
   PubMed Web of Science ®Google Scholar
• Klingebiel T, Cornish J, Labopin M, et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood. 2010;115(17):3437–3446. doi:10.1182/blood-2009-03-207001
   PubMed Web of Science ®Google Scholar
• Federmann B, Bornhauser M, Meisner C, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica. 2012;97(10):1523–1531. doi:10.3324/haematol.2011.059378
   PubMed Web of Science ®Google Scholar
• Lang P, Teltschik HM, Feuchtinger T, et al. Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. Br J Haematol. 2014;165(5):688–698. doi:10.1111/bjh.12810
   PubMed Web of Science ®Google Scholar
• Maschan M, Shelikhova L, Ilushina M, et al. TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. Bone Marrow Transplant. 2016;51:668–674. doi:10.1038/bmt.2015.343
   PubMed Web of Science ®Google Scholar
• Giardino S, Bagnasco F, Falco M, et al. Haploidentical stem cell transplantation after TCR-αβ+ and CD19+ cells depletion in children With congenital non-malignant disease. Transplant Cell Ther. 2022;28(7):394.e1–394.e9. doi:10.1016/j.jtct.2022.04.002
   PubMedGoogle Scholar
• Bethge WA, Eyrich M, Mielke S, et al. Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. Bone Marrow Transplant. 2022;57(3):423–430. doi:10.1038/s41409-021-01551-z
   PubMed Web of Science ®Google Scholar
• Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38:291–297. doi:10.1038/sj.bmt.1705445
   PubMed Web of Science ®Google Scholar
• Luznik L, Jalla S, Engstrom LW, et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98(12):3456–3464. doi:10.1182/blood.V98.12.3456
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650. doi:10.1016/j.bbmt.2008.03.005
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011. doi:10.1182/blood-2011-03-344853. Epub 2011 Apr 28. PMID: 21527516; PMCID: PMC3138683.
   Google Scholar
• Fuchs EJ, O’Donnell PV, Eapen M, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021;137(3):420–428. doi:10.1182/blood.2020007535
   PubMed Web of Science ®Google Scholar
• El Jurdi N, Martens MJ, Brunstein CG, et al. Health-related quality of life in double umbilical cord blood versus haploidentical marrow transplantation: a quality of life analysis report of BMT CTN 1101. Transplant Cell Ther. 2023;29(7):467.e1–467.e5. doi:10.1016/j.jtct.2023.04.009
   PubMedGoogle Scholar
• Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013 Jan;19(1):117–122. doi:10.1016/j.bbmt.2012.08.014. Epub 2012 Aug 29. PMID: 22940057.
   PubMed Web of Science ®Google Scholar
• Al Malki MM, Palmer J, Tsai NC, et al. Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. Blood Adv. 2022;6(14):4098–4106. doi:10.1182/bloodadvances.2022007264
   PubMed Web of Science ®Google Scholar
• Al-Homsi AS, Cirrone F, Wo S, et al. PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation. Blood Adv. 2023;7(14):3604–3611. doi:10.1182/bloodadvances.2023010545
   PubMed Web of Science ®Google Scholar
• Bejanyan N, Pidala JA, Wang X, et al. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021;5(5):1154–1163. doi:10.1182/bloodadvances.2020003779
   PubMed Web of Science ®Google Scholar
• Elmariah H, Otoukesh S, Kumar A, et al. Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide. Transplant Cell Ther. 2024;30(2):229.e1–229.e11. doi:10.1016/j.jtct.2023.11.010
   PubMedGoogle Scholar
• Idica A, Kaneku H, Everly MJ, et al. Elimination of post-transplant donor-specific HLA antibodies with bortezomib. Clin Transpl. 2008: 229–239. PMID: 19708459.
   PubMedGoogle Scholar
• Bailén R, Vicario JL, Solán L, et al. Management of donor-specific antibodies in haploidentical transplant: multicenter experience from the Madrid group of hematopoietic transplant. Front Immunol. 2021 May 19;12:674658. doi:10.3389/fimmu.2021.674658. PMID: 34093576; PMCID: PMC8170127.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Al Malki MM, Kongtim P, et al. Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv. 2021 Oct 26;5(20):4031–4043. doi:10.1182/bloodadvances.2021004862. PMID: 34474478; PMCID: PMC8945639.
   PubMed Web of Science ®Google Scholar
• Aguilera Agudo C, Gómez Bueno M, Krsnik Castello I. Daratumumab for antibody-mediated rejection in heart transplant-A novel therapy: successful treatment of antibody-mediated rejection. Transplantation. 2021;105(3):e30–e31. doi:10.1097/TP.0000000000003505
   PubMed Web of Science ®Google Scholar
• de Nattes T, Kaveri R, Farce F, et al. Daratumumab for antibody-mediated rejection: Is it time to target the real culprit? Am J Transplant. 2023 Jul 4. doi:10.1016/j.ajt.2023.06.018. Epub ahead of print. PMID: 37414251.
   PubMedGoogle Scholar
• Doberer K, Kläger J, Gualdoni GA, et al. Cd38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation. 2021 Feb 1;105(2):451–457. doi:10.1097/TP.0000000000003247. PMID: 32235256.
   PubMed Web of Science ®Google Scholar